M N 2 May 2024 CMB International Global Markets | Equity Research | Company Update WuXi AppTec (603259 CH) Steady 1Q performance amid challenging environment Target Price RMB53.23 WuXi AppTec reported 1Q24 revenue of RMB7,982mn, down 11.0% YoY, (Previous TP RMB67.53) attributable recurring net profit of RMB2,034mn, up 7.3% YoY, and attributable Up/Downside 21.9% adjusted non-IFRS net profit of RMB1,913mn, down 18.3% YoY. 1Q24 revenue Current Price RMB43.67 / adjusted Non-IFRS net income accounted for 20.4%/ ...

| RESEARCH 6 May, 2024 Nameson (01982.HK) Current Price HK$ 0.69 HKD, mn 2019/ Absolute 27.8% 38.0% 91.3% 63.3% TARGET PRICE HK$ - Expansion of cashmere yarn business: Nameson (01982.HK) entered into a JV agreement with its largest cashmere supplier, Hebei Yuteng, to engage in the manufacturing of cashmere yarn in Vietnam, the total production capacity per annum is designed to be 500 - 550 tonnes. Given the >80% utilization rate of cashmere yarn in Hebei, an increase in production capacity in Vietnam suppor ...

Investment Rating - The report maintains a "Buy" rating for EuroEyes (01846.HK) with a target price of HKD 6.92, indicating an upside potential from the current price of HKD 5.36 [4][11][20]. Core Insights - EuroEyes' overall performance in 2023 slightly fell short of expectations due to operational challenges at the London Vision Clinic and delayed clinic openings in Hong Kong and Germany. Despite this, demand for presbyopia correction treatments remained strong, leading to a 37.1% increase in lens exchange surgery revenue to HKD 371.8 million [7][11]. - The aging demographic is expected to drive demand for trifocal lens exchange surgery, which is anticipated to be a key growth driver for the company. The Knightsbridge clinic is projected to reach breakeven within 6 to 9 months, while the Hong Kong flagship clinic may take 1 to 2 years [8][11]. - The company plans to open new clinics in Kiel and Wiesbaden, Germany, by the end of the first half of 2024, and will also construct consultation centers in Beijing and Shanghai to enhance existing surgical center utilization [9][11]. - EuroEyes is pursuing an aggressive M&A strategy with a budget of HKD 500 million to acquire established practices in Europe, America, and Asia Pacific, aiming to complete these acquisitions within 24 months [11][19]. - The company has initiated a share buyback program to repurchase up to 3% of its outstanding shares, reflecting confidence in its future prospects [11]. Financial Performance - EuroEyes achieved a record turnover of HKD 714.3 million in 2023, marking a 17.0% year-on-year increase. Adjusted gross profit rose by 23.2% to HKD 339.4 million, with a gross profit margin of 47.5% [16][47]. - The adjusted net profit surged by 40.0% year-on-year to nearly HKD 141.7 million, resulting in a net profit margin of 19.8% [16][47]. - Revenue is projected to grow to HKD 842.7 million in 2024, with a year-on-year growth rate of 18.0% [47].

M N 30 Apr 2024 CMB International Global Markets | Equity Research | Company Update Weichai Power (000338 CH) 1Q24 net profit +40% YoY in line; solid growth outlook Target Price RMB20.40 While Weichai Power (Weichai)’s revenue growth of 6% YoY in 1Q24 is below (Previous TP RMB20.40) our expectation, net profit of RMB2.6bn (+40% YoY) accounted for 21.4% of our Up/Downside 15.0% full-year estimates (run rate in 1Q23: 20.5%), which is still in line with our Current Price RMB17.74 expectation. The earnings grow ...

Investment Rating - The report maintains a "BUY" rating for Weichai Power with a target price of HK$22.00, indicating a potential upside of 33.3% from the current price of HK$16.50 [4]. Core Insights - Weichai Power's net profit for 1Q24 increased by 40% year-on-year to RMB2.6 billion, driven by margin expansion in both its core business and KION Group [2]. - The revenue growth of 6% year-on-year to RMB56.4 billion in 1Q24 was below expectations, but the earnings growth was in line with forecasts [2]. - The company is positioned as a sector top pick due to its significant market share in natural gas engines and the expected structural growth from high-speed large-bore engines [2]. Financial Performance Summary - 1Q24 revenue was RMB56.4 billion, with a gross margin expansion of 3.4 percentage points year-on-year to 22.1% [2][6]. - Pre-tax profit surged by 58% year-on-year to RMB4.2 billion, with the core business and KION reporting growth rates of 45% and 93% respectively [2]. - Operating cash flow improved significantly to RMB1.6 billion in 1Q24, compared to an outflow of RMB471 million in 1Q23 [2]. KION Group Performance - KION, in which Weichai holds a 46.5% stake, reported an adjusted EBIT of EUR227 million in 1Q24, a 46% increase year-on-year, attributed to easing cost pressures [2][7]. - KION has set a full-year adjusted EBIT target of EUR790-940 million, reflecting a potential growth of 0-19% year-on-year [2][7]. Market Position and Sales - Weichai's multi-cylinder engine sales grew by 13% year-on-year to 206,000 units in 1Q24, outperforming the industry average, which saw a decline of approximately 1% [2][8]. - The company holds a market share of around 18% in the multi-cylinder engine segment, an increase of 2.3 percentage points year-on-year [2][8]. Earnings Forecast - Revenue projections for Weichai Power are as follows: FY24E at RMB236.3 billion, FY25E at RMB250.1 billion, and FY26E at RMB260.0 billion, with respective year-on-year growth rates of 10.4%, 5.8%, and 4.0% [3][13]. - Adjusted net profit estimates are RMB12.1 billion for FY24E, RMB13.1 billion for FY25E, and RMB13.8 billion for FY26E, reflecting growth rates of 34.4%, 7.7%, and 5.5% respectively [3][13].

Investment Rating - The report maintains a BUY rating for BYD with a target price of HK$262.00, indicating a potential upside of 21.1% from the current price of HK$216.40 [3][7]. Core Insights - Despite a net profit of RMB 4.6 billion in 1Q24 falling short of prior forecasts due to significant R&D spending of RMB 10.6 billion, BYD is still expected to meet the FY24E net profit forecast of RMB 33 billion [7]. - The report highlights that BYD's gross profit margin (GPM) in 1Q24 was better than expected, suggesting that price cuts implemented in February 2024 could be offset by cost reductions from suppliers [7]. - The forecast for FY24 sales volume growth of 20% remains achievable, supported by recent stimulus measures and overseas expansion [7]. Financial Summary - Revenue projections for FY24E are set at RMB 700,048 million, with expected growth to RMB 800,518 million in FY25E and RMB 884,971 million in FY26E [5][10]. - Net profit estimates for FY24E are RMB 33,109 million, increasing to RMB 40,173 million in FY25E and RMB 45,095 million in FY26E [5][10]. - The gross margin is projected to be 20.1% for FY24E, slightly decreasing to 19.5% in FY25E and 19.3% in FY26E [5][10]. Earnings and Valuation - The report indicates that BYD's earnings quality has not been prioritized in 1Q24, with expectations for more disciplined management of SG&A and R&D expenses in upcoming quarters [7]. - The net profit per vehicle in 1Q24 was RMB 7,300, which is lower than the previous quarter, reflecting the impact of price cuts on profitability [7]. - The report maintains FY24-25E net profit estimates largely unchanged while revising up both GPM and SG&A [7].

29 Apr 2024 CMB International Global Markets | Equity Research | Company Update Alphabet (GOOG US) 1Q24 earnings beat on efficiency gain; GenAI development on track Alphabet announced 1Q24 results: total revenue grew by 15% YoY to US$80.5bn, in line with consensus estimate; GAAP net income was up 57% YoY to US$23.7bn, 21% ahead of consensus estimate, thanks to Alphabet's organization optimization which leads to greater velocity and efficiency. The company further raised its shareholder return, announcing a ...

29 Apr 2024 CMB International Global Markets | Equity Research | Company Update GAC Group (2238 HK) In-line 1Q24 earnings GAC Group (GAC)'s 1Q24 results were largely in line with our prior estimates and we maintain our FY24E net profit forecast of RMB5.4bn. We are more conservative than management about Aion's sales volume and profitability, as we believe that Aion needs quality growth (brand upscale, overseas expansion etc.) in FY24E to lay out foundation for long-term development. We are of the view that ...

M N 29 Apr 2024 CMB International Global Markets | Equity Research | Company Update SANY Heavy (600031 CH) 2023 net profit a miss; 1Q24 still weak; Stay on the sidelines Target Price RMB14.80 SANY Heavy (SANY)’s net profit in 2023 came in at RMB4.53bn (+6% YoY), (Previous TP RMB12.30) which is 12% below both our and consensus estimates. In addition, net profit in Up/Downside (7.7%) 1Q24 only grew 5% YoY to RMB1.58bn due to a lack of revenue growth (-1% Current Price RMB16.04 YoY). We are still concerned abo ...

M N 29 Apr 2024 CMB International Global Markets | Equity Research | Company Update Tigermed (300347 CH) Meaningful demand recovery in 1Q24 Target Price RMB66.82 Tigermed reported 1Q24 revenue of RMB1,660mn, down 8.0% YoY, and (Previous TP RMB68.57) attributable recurring net income of RMB303mn, down 20.5% YoY, which was Up/Downside 15.8% mainly due to the substantially reduced gains on fair value changes and Current Price RMB57.70 investment changes (RMB8mn in 1Q24 vs RMB198mn in 1Q23). 1Q24 revenue / attr ...